BURLINGAME, CA, UNITED STATES, February 16, 2026 /EINPresswire.com/ -- The Global Business Landscape is being reshaped by rapid innovation, rising investment and ...

Over the past decade, cryo-electron microscopy has afforded scientists an unprecedented view deep into the core of tau fibrils, revealing shapes that track with different neurodegenerative diseases ...

Explore luminescence screening assays for drug discovery, including luciferase and ATP assays. Learn the principles, formats, ...

Avance Biosciences opened its new Potency and Cell-Based Assay Center of Excellence, a purpose-built facility designed to expand and centralize the company’s capabilities in potency and functional ...

OTC deficiency is a rare genetic condition and the most prevalent urea cycle disorder. Newborns with neonatal onset OTC deficiency exhibit hyperammonemia symptoms shortly after birth, including ...

Semarion, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, today announced it has raised ...

Chimeric antigen receptor (CAR) T cell-based therapy has greatly improved cancer treatment, especially for hematologic cancers. 1 By providing T cells with synthetic receptors that target tumor ...

Scientists use multi-day live cell assays to monitor cell growth, viability, and cytotoxicity when evaluating the effects of drug treatment. However, maintaining consistent cell health over time ...

This article examines target-based vs phenotypic screening, comparing mechanisms, advantages, limitations, and use cases to guide screening strategy selection in drug discovery.

Funding supports expansion of manufacturing and commercial capacity for SemaCyte microcarrier platform Semarion, a University of Cambridge spin-out company from the Cavendish Laboratory combining ...